Optimal Products | New HIV Drugs v2

The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study

The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....

GAP-f pDTG Implementation Considerations for National Programmes

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

Adult DRV/r (400/50mg) FAQs for Communities and PLHIV

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

Customizable Adult DRV/r (400/50mg) Healthcare Worker Training Slides

CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.

Adult DRV/r (400/50mg) Clinical Action Memo

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

Customizable Adult DRV/r (400/50mg) Prescribing Algorithm

CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r...

CHAI DRV/r 2L Product Profile

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

DRV/r (400/50mg) FAQs

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

Pediatric DTG Healthcare Worker Resources

CHAI has developed new resources to support healthcare worker decision-making and counselling around pDTG. pDTG HCW Worker Overview Video...

Pediatric DTG Implementation Memo (English, French)

CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric...

Transitioning to the 2021 WHO optimal formulary for antiretroviral drugs for children

This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal...

Community Resources for Pediatric DTG Scale-Up

Optimal and FASTER CAB members, with technical support from CHAI, developed a multi-media package of treatment literacy and advocacy...

2021 WHO Optimal Formulary and Limited-Use List for ARVs for Children

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for...

Pediatric DTG Clinical Studies Repository

A CHAI-curated repository of clinical studies in the development and implementation of pediatric DTG.

HIV New Product Introduction Toolkit